Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.

Talphera Inc.

In a report released yesterday, Naz Rahman from Maxim Group reiterated a Buy rating on Talphera, with a price target of $3.00. Rahman covers the He...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	TLPH	$1.34	+2.29%	182.05K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	TLPH	$1.34	+2.3%	182.05K
3
4
5
6

TLPH

TLPH

No Data Available

Get Talphera Inc. Data in Excel

Get Talphera Inc. Data in Excel